Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised, Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of the R21/Matrix-M1 Malaria Vaccine in Healthy African Women of Childbearing Potential in Mali

NCT06080243 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT06080243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06080243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised, Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of the R21/Matrix-M1 Malaria Vaccine in Healthy African Women of Childbearing Potential in Mali
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 19, 2025
Completion date
December 31, 2027
Enrollment
330 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy women of child bearing potential